The Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) drugs in development market research report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) and features dormant and discontinued products.
GlobalData tracks 98 drugs in development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) by 75 companies/universities/institutes. The top development phase for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) is phase i with 57 drugs in that stage. The Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline has 89 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline products market are: Merck, Hutchison MediPharma and AbbVie.
The key targets in the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline products market include Tyrosine Protein Kinase BTK, B Lymphocyte Antigen CD19, and B Lymphocyte Antigen CD20.
The key mechanisms of action in the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline product include Tyrosine Protein Kinase BTK Inhibitor with 25 drugs in Pre-Registration. The Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline products market including Small Molecule, and Monoclonal Antibody.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) overview
Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American Lymphoma Classification (REAL) and World Health Organization (WHO) classification.
For a complete picture of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
